Item 8.01 Other Events.

On December 6, 2022, Editas Medicine, Inc. (the "Company") issued a press release titled "Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease." A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.




Item 9.01       Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.                                        Description

99.1 Press release issued by the Company on December 6, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses